Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.
Overvalued
The company’s latest PE is 14.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 239.27M shares, decreasing 1.64% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 2.48M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.41.